|
|
Post by Clement on Aug 17, 2024 17:32:17 GMT -5
I think there have also been continuing equipment and labor capital investments to increase Tyvaso DPI production capacity which are in Collab & Services too. That goes to deferred revenue and eventually, yes, to Coll & Svcs. |
|
|
|
Post by sportsrancho on Aug 19, 2024 9:20:15 GMT -5
Can anyone tell me the name and address of the pharmacy that will sell you Afrezza for $99/mn? I’ve looked on the corporate website and couldn’t find any info on it or the MNKD assistance program. I’ve got liver problems and my glucose has been steadily climbing. It’s sterling pharmacy. How are you doing? Haven’t heard from you in a while… |
|
|
|
Post by dh4mizzou on Aug 28, 2024 8:37:59 GMT -5
Nice little jump this morning. But will it hold?
Update:
OK WTF is going on? Are the Shorts capitulating?
|
|
|
|
Post by Clement on Aug 28, 2024 8:55:55 GMT -5
Up 12% on very large volume in 30 minutes is a big jump. I'm guessing there's some news that is not released yet.
BTW, UTHR is up almost 4%. Maybe there's a connection.
|
|
|
|
Post by jkendra on Aug 28, 2024 8:59:42 GMT -5
Pretty hefty price target increases for both UTHR and MNKD.
|
|
nsmyth
Lab Rat
Posts: 43 
Sentiment: Long
|
Post by nsmyth on Aug 28, 2024 9:09:04 GMT -5
Maybe this?
2024-08-28 13:10:00 GMT DJ MannKind Price Target Raised to $12.00/Share From $10.00 by Oppenheimer
|
|
|
|
Post by BD on Aug 28, 2024 9:12:58 GMT -5
|
|
|
|
Post by tarheelblue004 on Aug 28, 2024 10:04:30 GMT -5
Dare I say I think today’s action may be better described by the technicals!? letitride called out the correlation between yesterday’s low volume and previous share price run ups…that seems more likely to me as to why this (crazy) jump than an analyst upgrade from $10 (already much higher than we are) to $12 (still much higher than we are). |
|
|
|
Post by BD on Aug 28, 2024 10:24:24 GMT -5
Looking like an early Christmas this year...
|
|
|
|
Post by dh4mizzou on Aug 28, 2024 10:26:19 GMT -5
BD. Not yet I'm holding out for the "GI Joe with the Kung-Fu Grip". ;-)
|
|
|
|
Post by minnlearner on Aug 28, 2024 10:35:58 GMT -5
IS "LUCY" HOLDING THE BALL?? (;  |
|
|
|
Post by dh4mizzou on Aug 28, 2024 10:40:54 GMT -5
Three bounces off $ 6.15 so far. Will be interesting to see when this goes IF MNKD can manage to break through that price.
|
|
|
|
Post by casualinvestor on Aug 28, 2024 10:44:37 GMT -5
Maybe the price target increase shook loose some short interest. I'd like to believe that there's some hidden news...but there's nothing expected for a couple months at the earliest.
|
|
|
|
Post by parrerob on Aug 28, 2024 10:52:07 GMT -5
There are also 3 conference participation early in the next 2 weeks.... may be some good staff can out-come as well. May be some other good target price raising, as well  Hopefully |
|
|
|
Post by prcgorman2 on Aug 28, 2024 10:52:20 GMT -5
I would like that the Oppenheimer raise on share price target and "analyst consensus" of STRONG BUY would be the reason for the sharp increase, but I would frankly be as surprised by that as I would by technical analysis being the reason. My suspicious nature wonders if there is news that hasn't yet broken.
I'm pleased that UTHR is part of the run up, because I've become increasingly concerned Boehringer Ingelheim (makers of Jardiance and Ofev) will consider a buyout of MannKind if the nintedanib DPI Phase 1 trial goes well (which I assume it should). I'm not against a buyout, but would be very sorry that it would happen now while the share price is less than $10 and where the premium on a BO would be about $12 per share.
I think a well-negotiated partnership for Ofev DPI could yield $1 to $2 EPS by 2030. Therefore I would much prefer technicals or analyst opinions (and fundamentals) be the reason for the increase in share price and so it comforts me UTHR is also enjoying a similar run because it implies there could be news other than a buyout, but perhaps still not publicly disclosed.
|
|
